The National Company Law Appellate Tribunal (NCLAT) has set aside a lower court order to liquidate debt-ridden Sterling Biotech, allowing its promoters to take back control of the company once they make full payment to...
Granules India to divest entire stake in Granules OmniChem to JV partner
Drug firm Granules India on Thursday announced divestment of its entire stake in its joint venture firm Granules OmniChem to its JV partner for an undisclosed sum. Granules OmniChem is an equal joint venture between...
Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion
Amgen Inc will buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year. Amgen, which...
Glenmark in talks to sell up to 30% in API biz to PremjiInvest
Glenmark Pharma is engaged in discussions with private equity fund PremjiInvest to sell 25-30% stake in Glenmark Life Sciences (GLS), the newly hived off subsidiary of active pharmaceutical ingredient (API) products...
Lupin divests its Japanese injectables business to Abu Dhabi company
Mumbai-headquartered Lupin on Thursday announced an agreement to sell its Japanese injectables business to neo ALA Co. Ltd, a wholly-owned subsidiary of Abu Dhabi-based Neopharma group. The company said that the move...
Who is next in big pharma’s merger spree?
Consolidation in the U.S. healthcare industry, which has already witnessed a string of multi-billion dollar deals, is expected to remain a major theme for the rest of 2019. Bristol-Myers Squibb’s $74 billion acquisition...
Sun Pharma announces tie-up for China foray; to develop 8 generic products
Sun Pharmaceutical Industries on Friday announced a partnership with China Medical System Holdings (CMS) to develop and commercialise generic drugs in mainland China. The tie-up will help the company make a foray into...
Japan pharmacy Cocokara surges 7% after merger talk report
Shares in Japan’s Cocokara Fine Inc jumped nearly 7% on Wednesday after a media report that it was in talks to be acquired by a larger rival to create the country’s biggest discount drugstore chain with $9.4 billion in...
Bayer buys BlueRock in $600 million bet on stem cell therapies
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline...
Cipla increases stake in consumer health biz to 100%, looks for tie-ups
Cipla is increasing its stake in its consumer health business to 100 per cent and is looking for tie ups with e-pharmacies for sales growth in the domestic market. On Wednesday the company announced it is acquiring a 26...
Malaysia’s Duopharma talks deals with trade war-hit Chinese firms
Duopharma Biotech (DUOP.KL), Malaysia’s largest generic drugmaker, is in talks with two Chinese consumer healthcare companies for expansion of their production base in Southeast Asia and a potential stake sale, its...
Aurobindo’s Sandoz deal may face further delays
Aurobindo Pharma Ltd’s plans to acquire Sandoz Inc.’s dermatology business, besides three manufacturing units in the US, is likely to be delayed further, pending approval from the Federal Trade Commission (FTC), the...
